You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEnoxacin
Accession NumberDB00467  (APRD00947)
TypeSmall Molecule
GroupsApproved
DescriptionA broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. [PubChem]
Structure
Thumb
Synonyms
1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid
1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
Enoxacin
Enoxacina
Énoxacine
Enoxacino
Enoxacinum
External Identifiers
  • AT 2266
  • CI 919
  • PD 107779
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlmitilNot Available
BactidanNot Available
ComprecinNot Available
EnoksetinNot Available
EnoxenNot Available
EnoxinNot Available
EnoxorPierre Fabre
EnoxorNot Available
EnroxilNot Available
FlumarkNot Available
GyramidNot Available
PenetrexNot Available
VinoneNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII325OGW249P
CAS number74011-58-8
WeightAverage: 320.3189
Monoisotopic: 320.128468635
Chemical FormulaC15H17FN4O3
InChI KeyIDYZIJYBMGIQMJ-UHFFFAOYSA-N
InChI
InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)
IUPAC Name
1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
SMILES
CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
Pharmacology
IndicationFor the treatment of adults (≥18 years of age) with the following infections caused by susceptible strains of the designated microorganisms: (1) uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae, (2) uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis, or Staphylococcus saprophyticus, and (3) complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae.
Structured Indications Not Available
PharmacodynamicsEnoxacin is a quinolone/fluoroquinolone antibiotic. Enoxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Enoxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. Enoxacin may be active against pathogens resistant to drugs that act by different mechanisms.
Mechanism of actionEnoxacin exerts its bactericidal action via the inhibition of the essential bacterial enzyme DNA gyrase (DNA Topoisomerase II).
TargetKindPharmacological actionActionsOrganismUniProt ID
DNA gyrase subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43700 details
DNA topoisomerase 4 subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43702 details
DNA topoisomerase 2-alphaProteinno
inhibitor
HumanP11388 details
Related Articles
AbsorptionRapidly absorbed following oral administration, with an absolute oral bioavailability of approximately 90%.
Volume of distributionNot Available
Protein bindingEnoxacin is approximately 40% bound to plasma proteins in healthy subjects and is approximately 14% bound to plasma proteins in patients with impaired renal function.
Metabolism

Hepatic. Some isozymes of the cytochrome P-450 hepatic microsomal enzyme system are inhibited by enoxacin. After a single dose, greater than 40% was recovered in urine by 48 hours as unchanged drug.

Route of eliminationNot Available
Half lifePlasma half-life is 3 to 6 hours.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Enoxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Enoxacin.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Enoxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Enoxacin.Experimental, Illicit
AcarboseEnoxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Enoxacin.Approved
AcenocoumarolEnoxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneAcetovanillone may increase the neuroexcitatory activities of Enoxacin.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Enoxacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Enoxacin.Approved
AlbiglutideEnoxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Enoxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Enoxacin.Experimental
AlogliptinEnoxacin may increase the hypoglycemic activities of Alogliptin.Approved
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Enoxacin.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Enoxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Enoxacin.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Enoxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Enoxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Enoxacin.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Enoxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Enoxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Enoxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Enoxacin.Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Enoxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Enoxacin.Approved, Investigational
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Enoxacin.Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Enoxacin.Approved, Vet Approved
Betulinic AcidBetulinic Acid may increase the neuroexcitatory activities of Enoxacin.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Enoxacin.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BromfenacBromfenac may increase the neuroexcitatory activities of Enoxacin.Approved
BromocriptineEnoxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Enoxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Enoxacin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Enoxacin.Approved
CalciumCalcium can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Nutraceutical
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium citrateCalcium citrate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CanagliflozinEnoxacin may increase the hypoglycemic activities of Canagliflozin.Approved
CarprofenCarprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the neuroexcitatory activities of Enoxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
ChlorpropamideEnoxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Enoxacin.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Enoxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Enoxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Enoxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Enoxacin.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Enoxacin.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Enoxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Enoxacin.Approved, Investigational
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Enoxacin.Investigational
DapagliflozinEnoxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Enoxacin.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Enoxacin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Enoxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Enoxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Enoxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Enoxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Enoxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
DicoumarolEnoxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Enoxacin.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Enoxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Enoxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Enoxacin.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Enoxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Enoxacin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Enoxacin.Approved
DisopyramideEnoxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Enoxacin.Approved, Investigational
DroxicamDroxicam may increase the neuroexcitatory activities of Enoxacin.Approved
DulaglutideEnoxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Enoxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Enoxacin.Approved
E6201E6201 may increase the neuroexcitatory activities of Enoxacin.Investigational
EbselenEbselen may increase the neuroexcitatory activities of Enoxacin.Investigational
EmpagliflozinEnoxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Enoxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Enoxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Enoxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Enoxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Enoxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
Ethyl biscoumacetateEnoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Enoxacin.Approved
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Enoxacin.Approved
ExenatideEnoxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Enoxacin.Investigational
FenbufenFenbufen may increase the neuroexcitatory activities of Enoxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Enoxacin.Approved
Ferric CarboxymaltoseThe serum concentration of Enoxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Enoxacin can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Enoxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
FloctafenineFloctafenine may increase the neuroexcitatory activities of Enoxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Enoxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Enoxacin.Approved
FluindioneEnoxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Enoxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Enoxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Enoxacin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Enoxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Enoxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Enoxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Enoxacin.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Enoxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Enoxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Enoxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Enoxacin.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Enoxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Enoxacin.Approved, Investigational, Withdrawn
GliclazideEnoxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideEnoxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideEnoxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideEnoxacin may increase the hypoglycemic activities of Glyburide.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Enoxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Enoxacin.Investigational
HMPL-004HMPL-004 may increase the neuroexcitatory activities of Enoxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Enoxacin.Approved, Vet Approved
IbuprofenIbuprofen may increase the neuroexcitatory activities of Enoxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Enoxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Enoxacin.Approved
IndomethacinIndomethacin may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Enoxacin.Withdrawn
Insulin AspartEnoxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirEnoxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineEnoxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineEnoxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanEnoxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproEnoxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Enoxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Enoxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Enoxacin can be decreased when it is combined with Iron saccharate.Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Enoxacin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Enoxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Enoxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Enoxacin.Approved
LanreotideEnoxacin may increase the hypoglycemic activities of Lanreotide.Approved
Lanthanum carbonateThe serum concentration of Enoxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
LiraglutideEnoxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Enoxacin.Investigational
LornoxicamLornoxicam may increase the neuroexcitatory activities of Enoxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Enoxacin.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium salicylateThe serum concentration of Enoxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Enoxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Enoxacin.Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Enoxacin.Investigational
MecaserminEnoxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Enoxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Enoxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Enoxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Enoxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Enoxacin.Withdrawn
MetforminEnoxacin may increase the hypoglycemic activities of Metformin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Enoxacin.Approved, Vet Approved
MifepristoneEnoxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolEnoxacin may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Enoxacin.Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Enoxacin.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Enoxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Enoxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Enoxacin.Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Enoxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
NateglinideEnoxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Enoxacin.Investigational
NCX 4016NCX 4016 may increase the neuroexcitatory activities of Enoxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Enoxacin.Approved
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Enoxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Enoxacin.Approved, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Enoxacin.Investigational
OctreotideEnoxacin may increase the hypoglycemic activities of Octreotide.Approved, Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Enoxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Enoxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Enoxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Enoxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Enoxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Enoxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Enoxacin.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Enoxacin.Approved, Vet Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Enoxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Enoxacin.Approved
PasireotideEnoxacin may increase the hypoglycemic activities of Pasireotide.Approved
PentamidineEnoxacin may increase the hypoglycemic activities of Pentamidine.Approved
PhenindioneEnoxacin may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonEnoxacin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Enoxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
PioglitazoneEnoxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Enoxacin.Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
PramlintideEnoxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Enoxacin.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Enoxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Enoxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Enoxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Enoxacin.Experimental
ProbenecidThe serum concentration of Enoxacin can be increased when it is combined with Probenecid.Approved
PropacetamolPropacetamol may increase the neuroexcitatory activities of Enoxacin.Approved
PTC299PTC299 may increase the neuroexcitatory activities of Enoxacin.Investigational
QuinaprilThe serum concentration of Enoxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinineEnoxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinideEnoxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Enoxacin.Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Enoxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Enoxacin.Investigational, Withdrawn
RosiglitazoneEnoxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalicylamideSalicylamide may increase the neuroexcitatory activities of Enoxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Enoxacin.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Enoxacin.Approved
SaxagliptinEnoxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SeratrodastSeratrodast may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
SevelamerSevelamer can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SitagliptinEnoxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SRT501SRT501 may increase the neuroexcitatory activities of Enoxacin.Investigational
Strontium ranelateThe serum concentration of Enoxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Enoxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineEnoxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleEnoxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Enoxacin.Approved
SulfisoxazoleEnoxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Enoxacin.Approved
SunitinibEnoxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Withdrawn
TenoxicamTenoxicam may increase the neuroexcitatory activities of Enoxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Enoxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Enoxacin.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Enoxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Enoxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Enoxacin.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Enoxacin.Approved
TolazamideEnoxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideEnoxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Enoxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Enoxacin.Approved
TranilastTranilast may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Enoxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Enoxacin.Approved, Vet Approved
Trisalicylate-cholineTrisalicylate-choline may increase the neuroexcitatory activities of Enoxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Enoxacin.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Enoxacin.Approved, Investigational
WarfarinEnoxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Enoxacin.Approved
ZileutonZileuton may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Enoxacin.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

DrugSyn.org

US4359578
General ReferencesNot Available
External Links
ATC CodesJ01MA04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (44.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8683
P-glycoprotein inhibitor INon-inhibitor0.8978
P-glycoprotein inhibitor IINon-inhibitor0.8606
Renal organic cation transporterNon-inhibitor0.7736
CYP450 2C9 substrateNon-substrate0.8078
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7557
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8862
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5351
Ames testAMES toxic0.9124
CarcinogenicityNon-carcinogens0.802
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8383 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6527
hERG inhibition (predictor II)Non-inhibitor0.5448
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point220-224 °CPhysProp
water solubility3.43 g/LNot Available
logP-0.20SANGSTER (1994) (ION-CORRECT)
Predicted Properties
PropertyValueSource
Water Solubility1.09 mg/mLALOGPS
logP-0.97ALOGPS
logP-0.98ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)5.5ChemAxon
pKa (Strongest Basic)8.59ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area85.77 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity83.95 m3·mol-1ChemAxon
Polarizability31.63 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthyridine carboxylic acids and derivatives. These are compounds containing a naphthyridine moiety, where one of the ring atoms bears a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassNaphthyridine carboxylic acids and derivatives
Direct ParentNaphthyridine carboxylic acids and derivatives
Alternative Parents
Substituents
  • Naphthyridine carboxylic acid
  • N-arylpiperazine
  • Pyridinylpiperazine
  • Fluoroquinolone
  • Pyridine carboxylic acid or derivatives
  • Pyridine carboxylic acid
  • Dialkylarylamine
  • Aminopyridine
  • Imidolactam
  • Pyridine
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Vinylogous amide
  • Tertiary amine
  • Azacycle
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Secondary aliphatic amine
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
Gene Name:
gyrA
Uniprot ID:
P43700
Molecular Weight:
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Yoshida H, Nakamura M, Bogaki M, Ito H, Kojima T, Hattori H, Nakamura S: Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob Agents Chemother. 1993 Apr;37(4):839-45. [PubMed:8388200 ]
  4. Weisser J, Wiedemann B: Elimination of plasmids by enoxacin and ofloxacin at near inhibitory concentrations. J Antimicrob Chemother. 1986 Nov;18(5):575-83. [PubMed:3542924 ]
  5. Courtright JB, Turowski DA, Sonstein SA: Alteration of bacterial DNA structure, gene expression, and plasmid encoded antibiotic resistance following exposure to enoxacin. J Antimicrob Chemother. 1988 Feb;21 Suppl B:1-18. [PubMed:2834313 ]
  6. Neuman M: Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121. [PubMed:3282749 ]
  7. Castora FJ, Vissering FF, Simpson MV: The effect of bacterial DNA gyrase inhibitors on DNA synthesis in mammalian mitochondria. Biochim Biophys Acta. 1983 Sep 9;740(4):417-27. [PubMed:6309236 ]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name:
parC
Uniprot ID:
P43702
Molecular Weight:
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Neuman M: Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121. [PubMed:3282749 ]
  4. Takahashi H, Hayakawa I, Akimoto T: [The history of the development and changes of quinolone antibacterial agents]. Yakushigaku Zasshi. 2003;38(2):161-79. [PubMed:15143768 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Molecular Weight:
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Maki T, Hirono I, Kondo H, Aoki T: Drug resistance mechanism of the fish-pathogenic bacterium Lactococcus garvieae. J Fish Dis. 2008 Jun;31(6):461-8. doi: 10.1111/j.1365-2761.2008.00927.x. [PubMed:18471102 ]
  3. Snyder RD, Cooper CS: Photogenotoxicity of fluoroquinolones in Chinese hamster V79 cells: dependency on active topoisomerase II. Photochem Photobiol. 1999 Mar;69(3):288-93. [PubMed:10089819 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23